Source comparison
CJC-1295 No DAC & Ipamorelin: Protocol Comparison
Receptor Target GHRH-R (cAMP pathway) GHS-R1a (calcium mobilisation) Dual pathway activation Synergistic protocols model physiological GH pulses most accurately Effective Dose Range (in vitro) 10–100 nM 1–10 nM 10 nM CJC + 1 nM Ipa Lower ipamorelin doses suffi
This comparison does not assign a generated winner or score.
- Receptor Target
- GHRH-R (cAMP pathway)
- GHS-R1a (calcium mobilisation)
- Dual pathway activation
- Synergistic protocols model physiological GH pulses most accurately
- Effective Dose Range (in vitro)
- 10–100 nM
- 1–10 nM
- 10 nM CJC + 1 nM Ipa
- Lower ipamorelin doses suffice when combined due to pathway convergence
- Peak GH Secretion Time
- 20–30 minutes post-exposure
- 15–25 minutes post-exposure
- 25–35 minutes (sustained peak)
- Combined treatment extends peak duration by 40–60% vs single-agent
- Receptor Desensitisation Onset
- 60 minutes (sustained exposure)
- 90 minutes (sustained exposure)
- 60 minutes (GHRH-R limits)
- Pulsed dosing every 90 min prevents desensitisation artifacts
- Serum Protein Binding
- 40–60% (high albumin affinity)
- 15–20% (low albumin affinity)
- Mixed (dose-adjust CJC upward)
- CJC-1295 requires 1.5–2× nominal concentration to account for binding loss
- Stability in Culture Media (37°C)
- 4–6 hours before significant degradation
- 8–12 hours (more stable structure)
- N/A (peptides assayed separately)
- Ipamorelin tolerates longer incubations; CJC-1295 requires fresh addition every 6 hours